SCHEMBL6418150

SCHEMBL6418150

COC(=O)/C=C/c1ccc(OC)cc1CN(CC(F)(F)F)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LY96 Q9Y6Y9 1/20 0.38
HDAC8 Q9BY41 4/20 0.37
KDM1A O60341 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MAOB P27338 1/20 0.37
CYP1A1 P04798 1/20 0.37
CYP1B1 Q16678 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CETP P11597 2/20 0.36
BACE1 P56817 1/20 0.35
ESR1 P03372 1/20 0.35
NR1H4 Q96RI1 2/20 0.35
JUN P05412 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418148 1.00 LY96 (0.38) LY96HDAC8KDM1AHDAC6MAOB
SCHEMBL7370771 0.91 PTGER4 (0.43) LY96HDAC8CYP1A1CYP1B1ALDH1A1
SCHEMBL7370769 0.91 PTGER4 (0.43) LY96HDAC8CYP1A1CYP1B1ALDH1A1
SCHEMBL6418090 0.85 CETP (0.47) HDAC8KDM1AHDAC6CYP1A1CYP1B1
SCHEMBL6418083 0.85 CETP (0.47) HDAC8KDM1AHDAC6CYP1A1CYP1B1
SCHEMBL6418683 0.82 SSTR4 (0.39) ALDH1A1MEN1KMT2ACETP
SCHEMBL4639101 0.81 ALDH1A1 (0.34) ALDH1A1MEN1KMT2ACETP
SCHEMBL4639106 0.81 ALDH1A1 (0.34) ALDH1A1MEN1KMT2ACETP
SCHEMBL6420626 0.79 POLB (0.38) ALDH1A1MAPTKMT2ACETP
SCHEMBL6418121 0.78 POLB (0.49) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0957917-B1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-12-07 EP disclosed
US-6825188-B2 MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN SMITHKLINE BEECHAM CORPORATION 2004-11-30 US disclosed
US-20040082559-A1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION 2004-04-29 US disclosed
US-20030125317-A1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082559-A1 Vitronectin receptor antagonists VCAM1, GPR174, ADGRF1 LY96 721/4885HDAC8 1892/4885KDM1A 4806/4885
US-20030125317-A1 Vitronectin receptor antagonists VCAM1, GPR174, ADGRF1 LY96 721/4885HDAC8 1892/4885KDM1A 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.